The management of the obese diabetic patient (Q35563453)

8 August 2017

1 reference

title

The management of the obese diabetic patient (English)

1 reference

8 August 2017

0 references

1 reference

Jeanine Albu

1

1 reference

8 August 2017

Nazia Raja-Khan

series ordinal

2

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14567159

22 March 2024

publication date

1 June 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0095454303000435?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00043-5

https://api.elsevier.com/content/article/PII:S0095454303000435?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00043-5

Primary Care: Clinics in Office Practice

22 March 2024

published in

1 reference

8 August 2017

30

1 reference

8 August 2017

2

1 reference

8 August 2017

465-491

1 reference

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The effect of age on the association between body-mass index and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The continuing epidemics of obesity and diabetes in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Weight change and diabetes incidence: findings from a national cohort of US adults

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Treatment of NIDDM with insulin agonists or substitutes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Insulin use in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glycation products and the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Standards of medical care for patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

New Pharmacological Approaches to Therapy of NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy of troglitazone on body fat distribution in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

An overview of the safety and tolerance of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Lessons from the glitazones: a story of drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Atherosclerosis in diabetes: the role of hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Monomeric insulins and their experimental and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

1 reference

7 January 2021

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Recombinant DNA technology in the treatment of diabetes: insulin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Obesity and type 2 diabetes: a conflict of interests?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Intentional weight loss and mortality among overweight individuals with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Temporal trends in BMI among adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Drug treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The impact of pharmacotherapy on weight management in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Current pharmacological approaches to the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Orlistat: in the prevention and treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Antiobesity pharmacotherapy in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Therapeutic fasting in morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Randomized trial of diet and gastroplasty compared with diet alone in morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Gastric bypass for treating severe obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Surgical treatment of obesity and its effect on diabetes: 10-y follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Surgical treatment of morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A case-control study of successful maintenance of a substantial weight loss: individuals who lost weight through surgery versus those who lost weight through non-surgical means

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Late outcome of isolated gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Treatment of diabetes in patients with severe obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Significant improvement in HbA1c in a morbidly obese type 2 diabetic patient after gastric bypass surgery despite relatively small weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Bariatric surgery. Surgery for weight control in patients with morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Biliopancreatic diversion

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Is Type II Diabetes Mellitus (NIDDM) a Surgical Disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Nonsurgical factors that influence the outcome of bariatric surgery: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Etiology of type II diabetes mellitus: role of the foregut

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Differentiated long-term effects of intentional weight loss on diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Results of the surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Gastric surgery for morbid obesity. The Adelaide Study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

1 reference

7 January 2021

Overview of bariatric surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Management of obesity in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Results and complications after adjustable gastric banding in a series of 250 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Laparoscopic bariatric surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900043-5

7 January 2021

Mode of action of orlistat

series ordinal

107

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00043-5

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference